1CDC. Interim pre-pandemic planning guidance: community strategy for pandemic influenza mitigation in the United States [R/OL]. 2007. http://www.cdc.gov/nonpharmaceutical- interventions/guidance/index.html.
2WHO. Update 49-SARS case fatality ratio, incubation period, 2003[R/OL]. http://www.who.int/csr/sars/archive/2003 05 07a/ en/print.html( 1 of 2).
3Yip PS, Lau EH, Lam KF, et al. A chain multinomial model for estimating the real-time fatality rate of a disease, with an application to severe acute respiratory syndrome [J]. Am J Epidemiol, 2005,161 (7) : 700-706.
4Yip PSF, Lain KF, Lau EHY, et al. A comparison study of realtime fatality rates: severe acute respiratory syndrome in Hong Kong, Singapore, Taiwan, Toronto and Beijing, China [J]. J Royal Star Soc(Series A) ,2005,168( 1 ) :233-243.
5Dormelly CA, Ghani AC, Leung GM, et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong [J]. Lancet, 2003,361 (9371) : 1761- 1766.
6Lam KF, Deshpande JV, Lau EHY, et al. A test for constant fatality rate of an emerging epidemic: with applications to severe acute respiratory syndrome in Hong Kong and Beijing [J]. Biometrics, 2008,64 : 869-876.
7Chen Z, Nakamura T. Statistical evidence for the usefulness of Chinese medicine in the treatment of SARS [J]. Phytotherapy Res, 2004,18: 592-594.
